Plutonium and Cesium decorporation after a nuclear accident

After a civil or military accident, involving nuclear material, dispersed radioactive metals contaminate both the environment and exposed populations within a perimeter which varies depending on the type of accident, wind strengths and other factors.
Today, there are no suitable decorporation treatments for large contaminated populations and no approved drug to be used after irradiation and free of serious side effects.
We are developing 2 drugs for the protection of populations, with special emphasis on children and pregnant women:
• decorporation of plutonium
• decorporation of cesium
The increasing threat of nuclear terrorism as well as accidents that involved the release of radioactive materials into the environment, such as accidents at the Chernobyl and Fukushima power plant, has heightened awareness for many nations for the need to be prepared for such cataclysmic events. Detonation of a nuclear weapon or a radiological dispersion device (“dirty bomb”) near densely populated areas could also result in a large number of individuals being contaminated by radionuclides via inhalation, ingestion, or through wounds. Internalization of radioactive materials may result in acute radiation sickness or chronic injuries including an increased risk of developing cancers.

The aim of decorporation treatments is to help the body eliminate radioactive or other toxic metals which have been accumulated in tissues.

The purpose of our decorporation drugs is to allow the body to eliminate radioactive or toxic metals that have accumulated in the tissues.

Plutonium decorporation (NU01)
Formulation of CaDTPA in the Aonys® microemulsion

Cesium decorporation (NU02)
Formulation of Prussian Blue in the Aonys® microemulsion

Collaboration with the French Atomic Energy Commissariat (CEA)

Radiation protection drug

NanoManganese (NP02) pour traiter les personnes irradiées après un accident sur un réacteur nucléaire